On June 15, 2022, Hong Kong Winhealth Pharma Group Ltd. (hereinafter referred to as "Winhealth Pharma") announced it has secured a license and distribution agreement with Quoin Pharmaceuticals Ltd. (hereinafter referred to as "Quoin") for two rare disease drug products, QRX003 and QRX004.
Quoin CEO, Dr. Michael Myers, said, “We are delighted to announce what we believe could ultimately become a transformational partnership for Quoin. Winhealth has extensive experience in successfully bringing innovative rare disease products to the market in China and South East Asia. Their roster of global partnerships is a testament to their commitment to serving the rare disease community and Quoin is excited at becoming the latest addition to this stellar list. Netherton syndrome is a devastating rare disease that severely affects patients and their quality of life, and causes tremendous stress to their families and nursing staff. Quoin's priority is to ensure that every patient, at anywhere, has access to our products once approved. This collaboration brings us one step closer to achieving this goal”.
Jack Wang, founder, chairman and CEO of Winhealth Pharma, said: "We are eager to have more excellent products to bring treatment solutions to rare disease patients in China. As an important partner of our global strategic cooperation, Quoin provides the contracted products that will bring hope for the treatment of rare disease patients. As an innovative bio-pharmaceutical company, Winhealth Pharma has always adhered to the original intention of 'Patient comes First, continuing to provide accessible and affordable treatment solutions for patients and families in need, and constantly improving the health ecosystem of rare diseases in China, so as to provide more extensive and in-depth services for patients with rare diseases. To this end, we are very much looking forward to the products benefiting Chinese patients as soon as possible. “
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
About Winhealth Pharma
Hong Kong Winhealth Pharma Group is a China-based, global innovative biomedical company founded in 2006, providing novel breakthrough therapies to patients with rare diseases and other unmet medical needs. The Group has established long-term strategic partnership with dozens of world-leading biotechnology companies. It has built a unique, balanced and diversified portfolio with numerous orphan drugs and specialty products at commercial and late clinical stages, and will continuously look to bring in more innovative therapies from the globe. For more information, http://www.winhealth.hk please visit or follow “Winhealth Pharma” on WeChat.
Forward-looking statement
This announcement contains forward-looking statements, reflecting the current beliefs and expectations of Winhealth Pharma Group (HK). These statements are based on expectations and assumptions about the current available information and are subject to known and unknown risks and uncertainties that may cause actual results to differ significantly from such statements. Risks and uncertainties include domestic and international macroeconomic conditions such as the overall market situation and changes in the interest rate or the currency exchange rate. These risks and uncertainties are especially applicable to the forward-looking statement related to the products. Risks and uncertainties related to the products include but are not limited to completion and termination of clinical trials; regulatory approvals; statements and concerns regarding product safety and efficacy; technological advances; adverse outcomes of major litigation; domestic and foreign healthcare reforms and changes in laws and regulations. In addition, there are manufacturing and marketing risks for existing products, including but not limited to inability to meet demand in production capacity, availability of raw materials and entry of competing products into the market, and force majeure. We have no willingness or obligation to update or modify any forward-looking statements, whether as a result of additional information, future events or other circumstances.